Filing summary
Issuer discrepancy: The request identifies Newegg Commerce, Inc., but the supplied Form 10-Q is for Dehaier Medical Systems Limited, a British Virgin Islands company operating in China. This summary covers the filing provided; confirm the issuer before relying on it.
Business context and reporting period
Unaudited results cover the three and six months ended June 30, 2011, compared with the same periods in 2010. Dehaier distributes and sells medical devices, respiratory and oxygen homecare products, and technical-service products, mainly in China. It sells branded products and equipment from third-party manufacturers. The filing was signed August 11, 2011.
Financial performance and liquidity
Amounts are in U.S. dollars. Margins are calculated from reported figures.
| Metric | Six months 2011 | Six months 2010 | Three months 2011 | Three months 2010 |
|---|---|---|---|---|
| Revenue | $10.67m | $7.47m | $7.71m | $4.83m |
| Gross profit | $3.84m | $2.89m | $2.84m | $1.92m |
| Gross margin | 36.0% | 38.7% | 36.8% | 39.7% |
| Operating income | $2.22m | $2.00m | $1.93m | $1.36m |
| Operating margin | 20.8% | 26.8% | 25.0% | 28.1% |
| Net income attributable to Dehaier | $1.94m | $1.66m | $1.74m | $1.14m |
| Basic and diluted EPS | $0.43 | $0.46 | $0.39 | $0.27 |
- Growth and mix: Revenue increased 42.7% for the first half and 59.7% in Q2. Medical-device revenue was $7.07m for the first half; respiratory and oxygen homecare revenue rose to $2.01m from $0.90m. Management attributed growth to unit sales, repeat hospital customers and government projects. Q2 government-project revenue was nearly $2.60m.
- Costs and margins: First-half cost of revenue rose 49.1%, faster than revenue, and operating expenses rose 70.5%. General and administrative costs increased 95.3%, including public-company and R&D costs; selling expense rose 43.8%. Gross and operating margins declined year over year in both comparative periods.
- Cash flow: First-half operating cash use was $3.36m, improving from $4.62m used in 2010, but remained negative. Investing cash use was $0.06m; financing provided $0.01m, versus $9.94m in 2010, when IPO proceeds were received. Cash fell to $3.01m from $5.92m at year-end 2010. Working-capital investment included a $3.45m increase in accounts receivable and a $4.24m increase in prepayments and other current assets.
- Balance sheet and debt: Current assets were $38.98m and current liabilities $13.88m, giving reported working capital of $25.10m. Short-term borrowings were $1.55m, under a variable-rate credit line averaging 6.94%; the line renews annually and is secured by a subsidiary’s building and guaranteed by the operating subsidiary and an officer. The company stated available working capital should fund operations for at least 12 months.
- Other balance-sheet items: Accounts receivable was $12.56m; prepayments and other current assets were $9.54m, including $7.76m prepaid for equipment; VAT receivable was $4.43m; and tax payable was $10.35m. Tax receivable and tax payable are not interchangeable, and the filing does not explain their expected settlement timing in detail.
Changes, outlook, risks and unusual items
- Management expects continued spending on R&D, public-company costs, sales staff, promotion and customer-experience centers. It did not provide quantitative earnings or revenue guidance and cautioned that interim results may not indicate future performance.
- In June, Dehaier signed a supply agreement with Beijing Hospital 301 for equipment valued at approximately $1.32m. Other initiatives included a rural-healthcare cooperation project, Taiwan distribution authorization for CPAP devices, and three new PRC patents. In July, after the reporting period, it opened a Beijing oxygen-filling facility/service center and a Shanghai customer-experience center.
- Dehaier was preparing FDA and CE applications for some homecare products; none had been approved, and approval was not assured. The high-technology tax certification supporting BDL’s 15% tax rate was due to expire in 2012.
- A $149,867 first-half gain from a decrease in the fair value of warrant liabilities increased reported pretax income; the corresponding Q2 gain was $140,341. This is a fair-value adjustment, not operating revenue. Foreign-currency translation added $511,375 to first-half comprehensive income.
- The company had not filed certain prior-year VAT returns for some customers, but said potential VAT liabilities were accrued. Estimated possible employee severance payments of about $229,000 were not recorded because management judged payment unlikely. Operating leases required approximately $881,100 in future minimum payments as of June 30, 2011.
- Revenue was concentrated: one customer accounted for about 13% of first-half revenue. The three top-selling products accounted for about 80% of first-half revenue versus 56% in 2010. The filing reports no legal proceedings and describes disclosure controls as effective; it lists risk factors as “Not applicable.”
Important facts for investors to verify
- Confirm that this Dehaier filing—not a Newegg filing—is the intended document.
- Assess collection of receivables and recoverability/timing of VAT credits and supplier prepayments, given negative operating cash flow and the increase in working-capital balances.
- Review the VAT-return status, accrued tax exposure and the substantial tax-payable balance.
- Verify government-project revenue, delivery and collection, and whether the Hospital 301 agreement contributes recognized revenue or cash.
- Evaluate product and customer concentration, the planned growth and economics of home oxygen services, and the 2012 high-technology certification renewal and pending FDA/CE applications.
- Confirm renewal and repayment terms for the secured short-term credit line and the adequacy of liquidity if collections or project execution are delayed.